Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 31, 2022

BUY
$198.88 - $227.6 $182,969 - $209,392
920 New
920 $217,000
Q3 2021

Nov 09, 2021

SELL
$212.27 - $248.7 $195,288 - $228,804
-920 Closed
0 $0
Q1 2021

May 10, 2021

BUY
$221.91 - $258.6 $204,157 - $237,912
920 New
920 $230,000
Q4 2020

Feb 04, 2021

SELL
$216.38 - $257.67 $199,069 - $237,056
-920 Closed
0 $0
Q4 2019

Jan 31, 2020

SELL
$189.21 - $243.2 $37,842 - $48,640
-200 Reduced 17.86%
920 $221,000
Q2 2019

Feb 13, 2020

BUY
$166.7 - $195.41 $186,704 - $218,859
1,120 New
1,120 $248,000
Q2 2019

Jul 17, 2019

SELL
$166.7 - $195.41 $186,704 - $218,859
-1,120 Closed
0 $0
Q2 2018

Jul 17, 2018

SELL
$166.05 - $186.51 $33,210 - $37,302
-200 Reduced 15.15%
1,120 $219,000
Q1 2018

Feb 13, 2020

BUY
$169.43 - $198.0 $223,647 - $261,360
1,320 New
1,320 $292,000
Q1 2018

May 01, 2018

SELL
$169.43 - $198.0 $223,647 - $261,360
-1,320 Closed
0 $0
Q4 2017

Jan 29, 2018

SELL
$168.79 - $188.59 $69,372 - $77,510
-411 Reduced 23.74%
1,320 $230,000
Q3 2017

Oct 23, 2017

BUY
$167.29 - $191.0 $289,578 - $330,621
1,731
1,731 $323,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $149B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Nottingham Advisors, Inc. Portfolio

Follow Nottingham Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nottingham Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nottingham Advisors, Inc. with notifications on news.